Related Experiment Video

Updated: Jun 2, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report

Richard T Silver1, Katherine Vandris, Joshua J Goldman

  • 1Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA. rtsilve@med.cornell.edu

Blood
|April 27, 2011
PubMed

Insights

Recombinant interferon-alfa (rIFNα) shows promise for early primary myelofibrosis patients. Over 80% experienced clinical benefit or stability, with some marrow reversion, suggesting rIFNα as a viable treatment option.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Primary myelofibrosis (PM) has limited effective treatments.
  • Early-stage PM patients with residual hematopoiesis and low-grade fibrosis require novel therapeutic approaches.

Purpose of the Study:

  • To prospectively evaluate the efficacy and safety of recombinant interferon-alfa (rIFNα) in early primary myelofibrosis patients.
  • To assess treatment response using International Working Group for Myelofibrosis Research and Treatment criteria.

Main Methods:

  • Seventeen "early" PM patients received either rIFNα-2b or pegylated rIFNα-2a.
  • Treatment involved doses ranging from 500,000 to 3 million units thrice weekly or 45-90 μg weekly.
  • Patient prognosis and response were monitored.

Main Results:

  • Over 80% of patients (14/17) achieved clinical benefit or disease stability.
  • Two patients achieved complete remission, and seven achieved partial remission.
  • Four patients had stable disease, and four showed improvement in marrow morphology.

Conclusions:

  • Recombinant interferon-alfa demonstrates significant clinical benefit and stability in early primary myelofibrosis.
  • The treatment is associated with acceptable toxicity and documented marrow reversion.
  • Expanded evaluation of rIFNα for early PM is warranted.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...